Patent intelligence · US
US 11504364
Inhibitors of fibroblast activation protein
Inhibitors of fibroblast activation protein
Patent details — US 11504364
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 22, 2022
- Expiration
- Nov 17, 2042
- Applicant
- PRAXIS BIOTECH LLC
- Claims
- 37
- CPC classes
- A61K, A61K31/216, A61K31/4709, A61K45/06
Quick answer
US 11504364 (Inhibitors of fibroblast activation protein) is held by PRAXIS BIOTECH LLC. Status: granted. Granted Nov 22, 2022. Expires Nov 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PRAXIS BIOTECH LLC
- Grant date
- Expiration
- Claims
- 37
- CPC classes
- A61K, A61K31/216, A61K31/4709, A61K45/06, A61P, A61P35/00
More from PRAXIS BIOTECH LLC
Related pharmaceutical patents in our USPTO index.
-
US 12404297
Salts and crystal forms of GABA-A positive allosteric modulator
granted -
US 12325711
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-α]pyrazine as an ion channel modulator
granted -
US 12259378
Dynamic clamps and methods of use thereof
granted -
US 12145939
Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
granted -
US 12077502
Formulations of T-type calcium channel modulators and methods of use thereof
granted -
US 11918571
Compounds and their methods of use
granted -
US 11919836
Prodrugs of fencamfamine
granted -
US 11866439
Ion channel modulators
granted
Frequently asked questions
What is US patent 11504364?
US 11504364 (Inhibitors of fibroblast activation protein) is held by PRAXIS BIOTECH LLC. Status: granted. Granted Nov 22, 2022. Expires Nov 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11504364?
PRAXIS BIOTECH LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 11504364 expire?
Our index shows an expiration date of Nov 17, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.